At Ascend we aim high. Ascend was founded to address the need for quality manufacturing capacity for any gene and cell therapy developer. We offer starting material, process and formulation development, clinical manufacturing, analytical and regulatory support to biotech companies working in advanced modalities who need flexible chemistry, manufacturing and controls (CMC) services. Our team of approximately 120 cross-functional experts in the UK, Germany and United States are on a mission to create the most effective, highest-quality, scalable gene therapies possible. Operating an efficient, streamlined model, we provide more than just a service. We’re a team of highly skilled, experienced individuals with a hunger to help you succeed – whether that’s by innovating new techniques and solving unexpected problems, or by offering honest advice. With origins in biopharma, our expert teams have “been there and done that” with regulators. They understand the quality and potency of your product is just as important as the yield. Beyond that, the Ascend specialists have the next-generation platforms and capabilities you need to ensure clinical and commercial success. The result? Consistently high quality and low risk for you. Put simply, we offer the service you need for you to Aim Higher.
Location: United Kingdom, England, Potters Bar
Employees: 51-200
Total raised: $199.1M
Founded date: 2021
Investors 2
Date | Name | Website |
12.05.2023 | DCVC | dcvc.com/ |
- | Cathay Hea... | health.cat... |
Funding Rounds 2
Date | Series | Amount | Investors |
09.05.2023 | - | $132.5M | - |
28.02.2023 | - | $66.6M | - |
Mentions in press and media 4
Date | Title | Description |
18.05.2023 | 4BIO Capital Participates in $130M Funding of New Gene and Cell Manufacturing Specialist Ascend | Expert transatlantic teams merge to establish Ascend as new facilitator for gene and cell therapy companies to translate product ideas into viable clinical programs |
09.05.2023 | Ascend Completes Series A; Raises $132.5M in Total | Ascend Gene & Cell Therapies, a London, UK-based company innovating manufacturing processes for gene therapy technologies, raised an undisclosed amount in Series A funding. The round, which brought the total amount raised to date to $13... |
09.05.2023 | Biotech Ascend Gene & Cell Therapies raises £105m | London-based biotech firm Ascend Gene & Cell Therapies has raised $132.5m (£105.1m) for its gene therapy manufacturing technology. Founded by the VC firm Monograph Capital in 2021, Ascend helps gene therapy companies to transition their... |
- | Ascend | “Ascend Gene & Cell Therapies” |